FATE News and Press, Fate Therapeutics Inc. From 08/12/25

2025-08-12 16:45:29 ET More on Fate Therapeutics Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics Financial information for Fate Therapeutics Read the full article on Seeking Alpha For further det...

First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus erythematosus (DORIS) at 12-month follow-up Held init...

Reeds Inc. (REED) is expected to report $-0.04 for Q2 2025 Jerash Holdings (US) Inc. (JRSH) is expected to report for Q1 2026 Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2025-06-30 Verde Clean Fuels Inc. (VGAS) is expected to report for Q2 2025 Mobile In...

Fate Therapeutics Inc. (FATE) is expected to report $-0.35 for Q2 2025

2025-08-11 18:45:12 ET Fate Therapeutics, Inc. (FATE) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 7.59%. The average open to low on the day of earnings was -7.28%. The average open t...

2025-08-11 18:40:12 ET Fate Therapeutics, Inc. (FATE) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in FATE stock price following earnings has averaged ±2.85% , with a median of 2.09%. ...

All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in drug-free Definition of Remission in SLE (DORIS) First extrarenal SLE patie...

SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Ma...

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced that c...

GT Biopharma (NASDAQ: GTBP) just initiated the dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies. Unfortunately, relapsed/refractory CD33 expressing hematologic mal...